GigaLab by Parse Biosciences: Transforming cell sequencing for drug discovery and AI

Parse Biosciences, a pioneer in single cell sequencing, has announced its groundbreaking GigaLab—a transformative lab designed to upscale single cell sequencing capacity to billions of cells annually. The GigaLab is built upon Parse’s innovative Evercode technology, enhancing throughput with expanded automation and a more robust workflow, enabling scientific advancements in cell profiling previously unimaginable.

GigaLab’s Pioneering Scale for Large-Scale Research Initiatives

Designed specifically to handle high-capacity projects, GigaLab offers unprecedented scalability, supporting research on 10 million cells and above. The lab’s initial capacity allows for profiling up to 2.5 billion cells each year, a figure expected to grow as the platform evolves. Current GigaLab projects are already surpassing cell counts found in all publicly accessible single cell datasets. These advancements are set to significantly impact fields including drug discovery, generative AI dataset creation, and large-scale population studies.

Collaborative Research Pushes New Boundaries in Cell Profiling

In a pioneering demonstration, Parse Biosciences collaborated with Ultima Genomics, the developer of an ultra-high-throughput sequencing platform, on a project that sequenced 10 million cells in a single run with 1,092 samples. Completed within just three days, this study mapped 90 cytokine perturbations across 18 immune cell types from 12 PBMC donors, recording over 19,000 cellular perturbations. Professor Fabian Theis, a renowned computational biology expert from Helmholtz Munich, is currently analyzing this vast dataset using Scanpy, his lab’s computational tool, and applying it to train AI models focused on health and disease prediction.

Professor Theis remarked that Parse’s capacity for generating large-scale single cell perturbation datasets is essential for advancing predictive modeling in health and disease contexts. He further emphasized that Parse’s rapid data generation would accelerate discoveries within the field.

Unprecedented Capabilities for Transformative Biological Discovery

Parse Biosciences’ CTO, Dr. Charlie Roco, highlighted that the company’s Evercode technology has empowered researchers to profile up to 1 million cells in a single experiment. Dr. Roco affirmed that the GigaLab is setting new standards in the field, creating unparalleled opportunities to advance human health and biological understanding.

Upcoming GigaLab Presentation at ASHG Conference

Parse Biosciences will reveal more about the GigaLab’s capabilities at the American Society of Human Genetics (ASHG) conference, presenting at the CoLab Theater on November 6. The Parse team will also be available throughout the event at Booth #703 to discuss their work further.